Gene amplification of ribosomal protein S6 kinase-1 and -2 in gastric cancer

Anticancer Research

Volumn 33, Issue 2, 2013, Pages 469-476

  Yoshida, Shuhei ^a,b   Matsumoto, Kazuko ^a   Arao, Tokuzo ^a   Taniguchi, Hirokazu ^c   Goto, Isao ^b   Hanafusa, Toshiaki ^b   Nishio, Kazuto ^a   Yamada, Yasuhide ^d  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

^c Tokyo Medical and Dental University   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Gastric cancer; Gene amplification; Ribosomal protein S6 kinase; RPS6KB2; S6K2 mTOR signaling

Indexed keywords

COMPLEMENTARY DNA; GENOMIC DNA; MAMMALIAN TARGET OF RAPAMYCIN; RIBOSOMAL PROTEIN S6 KINASE 1; RIBOSOMAL PROTEIN S6 KINASE 2; RIBOSOME PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; COMPARATIVE GENOMIC HYBRIDIZATION; ESOPHAGUS CANCER; GENE AMPLIFICATION; GENE DOSAGE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; STOMACH CARCINOMA; UPREGULATION;

ADENOCARCINOMA; AGED; BLOTTING, WESTERN; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84875875296     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Bittoni A, Maccaroni E, Scartozzi M, Berardi R and Cascinu S: Chemotherapy for locally advanced and metastatic gastric cancer: state of the art and future perspectives. Eur Rev Med Pharmacol Sci 14: 309-314, 2010.
2. Fujii M, Kochi M and Takayama T: Recent advances in chemotherapy for advanced gastric cancer in Japan. Surg Today 40: 295-300, 2010.
3. Pópulo H, Lopes JM and Soares P: The mTOR Signalling Pathway in Human Cancer. Int J Mol Sci 13: 1886-1918, 2012.
4. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P and Sabatini DM: Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14: 1296-1302, 2004.
5. Nojima H, Tokunaga C, Eguchi S, Oshiro N, Hidayat S, Yoshino K, Hara K, Tanaka N, Avruch J and Yonezawa K: The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem 278: 15461-15464, 2003.
6. Magnuson B, Ekim B and Fingar DC: Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signaling networks. Biochem J 441: 1-21, 2012.
7. Pearce LR, Komander D and Alessi DR: The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol 11: 9-22, 2010.
8. Faivre S, Kroemer G and Raymond E: Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5: 671-688, 2006.
9. Dancey J: mTOR signaling and drug development in cancer. Nat Rev Clin Oncol 7: 209-219, 2010.
10. Matsumoto K, Arao T, Hamaguchi T, Shimada Y, Kato K, Oda I, Taniguchi H, Koizumi F, Yanagihara K, Sasaki H, Nishio K and Yamada Y: FGFR2 gene amplification and clinicopathological features in gastric cancer. Br J Cancer 106: 727-732, 2012.
11. Matsumoto K, Arao T, Tanaka K, Kaneda H, Kudo K, Fujita Y, Tamura D, Aomatsu K, Tamura T, Yamada Y, Saijo N and Nishio K: mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. Cancer Res 69: 7160-7164, 2009.
12. Furuta K, Arao T, Sakai K, Kimura H, Nagai T, Tamura D, Aomatsu K, Kudo K, Kaneda H, Fujita Y, Matsumoto K, Yamada Y, Yanagihara K, Sekijima M and Nishio K: Integrated analysis of whole-genome exon array and array-comparative genomic hybridization in gastric and colorectal cancer cells. Cancer Sci 103: 221-227, 2012.
13. Dobashi Y, Suzuki S, Kimura M, Matsubara H, Tsubochi H, Imoto I and Ooi A: Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/AKT in human lung carcinomas. Hum Pathol 42: 214-226, 2011.
14. Zhou L, Huang Y, Li J and Wang Z: The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol 27: 255-261, 2010.
15. Couch FJ, Wang XY, Wu GJ, Qian J, Jenkins RB and James CD: Localization of PS6K to chromosomal region 17q23 and determination of its amplification in breast cancer. Cancer Res 59: 1408-1411, 1999.
16. Bärlund M, Forozan F, Kononen J, Bubendorf L, Chen Y, Bittner ML, Torhorst J, Haas P, Bucher C, Sauter G, Kallioniemi OP and Kallioniemi A: Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst 92: 1252-1259, 2000.
17. Wu GJ, Sinclair CS, Paape J, Ingle JN, Roche PC, James CD and Couch FJ: 17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGma1B genes. Cancer Res 60: 5371-5375, 2000.
18. Adem C, Soderberg CL, Hafner K, Reynolds C, Slezak JM, Sinclair CS, Sellers TA, Schaid DJ, Couch F, Hartmann LC and Jenkins RB: ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers. Genes Chromosomes Cancer 41: 1-11, 2004.
19. Bärlund M, Monni O, Kononen J, Cornelison R, Torhorst J, Sauter G, Kallioniemi OLLI-P and Kallioniemi A: Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. Cancer Res 60: 5340-5344, 2000.
20. Ehrbrecht A, Müller U, Wolter M, Hoischen A, Koch A, Radlwimmer B, Actor B, Mincheva A, Pietsch T, Lichter P, Reifenberger G and Weber RG: Comprehensive genomic analysis of desmoplastic medulloblastomas: Identification of novel amplified genes and separate evaluation of the different histological components. J Pathol 208: 554-563, 2006.
21. Zhao MY, Auerbach A, D'Costa AM, Rapoport AP, Burger AM, Sausville EA, Stass SA, Jiang F, Sands AM, Aguilera N and Zhao XF: Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy. Clin Cancer Res 15: 1708-1720, 2009.
22. Watanabe T, Imoto I, Kosugi Y, Ishiwata I, Inoue S, Takayama M, Sato A and Inazawa J: A novel amplification at 17q21-23 in ovarian cancer cell lines detected by comparative genomic hybridization. Gynecol Oncol 81: 172-177, 2001.
23. Pérez-Tenorio G, Karlsson E, Waltersson MA, Olsson B, Holmlund B, Nordenskjöld B, Fornander T, Skoog L and Stål O: Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer. Breast Cancer Res Treat 128: 713-723, 2011.
24. Karlsson E, Waltersson MA, Bostner J, Pérez-Tenorio G, Olsson B, Hallbeck AL and Stål O: High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1. Genes Chromosomes Cancer 50: 775-787, 2011.